Jefferies Sees $7 in EPS Upside for Haemonetics (HAE) After CSL/Terumo Announcement
Tweet Send to a Friend
Jefferies analyst Anthony Petrone reiterated a Buy rating and $185.00 price target on Haemonetics (NYSE: HAE) after CSL and Terumo ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
